Silong Xiang

机构：Shijiazhuang Yiling Pharmaceutical (China)

发表论文 10 篇 · 总被引 238 次 · h-index 6

代表论文

• Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors (2021 · Journal of Hematology & Oncology · 被引 150)
• Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors (2022 · Investigational New Drugs · 被引 53)
• Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer (2024 · Gynecologic Oncology · 被引 9)
• First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors (2024 · npj Precision Oncology · 被引 9)
• Construction and characterization of an infectious replication competent clone of porcine endogenous retrovirus from Chinese miniature pigs (2013 · Virology Journal · 被引 7)
• Efficacy and safety of enlonstobart (SG001), a PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer: A multicenter, single-arm, open-label, phase II study. (2024 · Journal of Clinical Oncology · 被引 6)